Table 1.
Patient characteristics
| A091201 Patient Characteristics | ||||
|---|---|---|---|---|
| 1 (N=31) | 2 (N=15) | Total (N=46) | p value | |
| Age | 0.2409 | |||
| Median | 60.0 | 67.0 | 62.5 | |
| Gender | 0.7406 | |||
| M | 17(54.8%) | 9 (60.0%) | 26 (56.5%) | |
| Race | ||||
| White | 31 (100.0%) | 15 (100.0%) | 46 (100.0%) | |
| ECOG Performance Status | 0.1571 | |||
| 0 | 23 (74.2%) | 8 (53.3%) | 31 (67.4%) | |
| 1 | 8 (25.8%) | 7 (46.7%) | 15 (32.6%) | |
| Prior treatment with a MEK Inhibitor | 0.4819 | |||
| No | 30 (96.8%) | 15 (100.0%) | 45 (97.8%) | |
| Site of meta static disease | 0.5924 | |||
| Liver (only) | 15 (48.4%) | 6 (40.0%) | 21 (45.7%) | |
| Other site | 16 (51.6%) | 9 (60.0%) | 25 (54.3%) | |
| Elevated LDH | 0.1094 | |||
| Yes | 22 (71.0%) | 7 (46.7%) | 29 (63.0%) | |
| Liver | 0.3145 | |||
| Yes | 29 (93.5%) | 15 (100.0%) | 44 (95.7%) | |
| Bone | 0.8423 | |||
| No | 24 (77.4%) | 12 (80.0%) | 36 (78.3%) | |
| Prior systemic therapy* | 0.7661 | |||
| Yes | 11 (35.5%) | 6 (40.0%) | 17 (37.0%) | |
| Prior hepatic arterial embolization (HAE) | 0.9676 | |||
| Yes | 4 (12.9%) | 2 (13.3%) | 6 (13.0%) | |
*
Includes three treatments of hepatic immunoembolization not captured in HAE (all three in Arm 1)